Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.01% atropine dosing frequency study in children with low myopia
ChiCTR2200057647Phase 3Not yet recruiting
- Sponsor
- Shanghai Eye Disease Prevention & Treatment Center
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atropine in myopia (2 arms), sponsored by Shanghai Eye Disease Prevention & Treatment Center. Primary endpoint: axial length. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on ChiCTR2200057647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057647.